Kevin Caldwell, Ossium’s CEO, Co-Founder & President, recently presented an update on our bone marrow transplant study at the 2023 Congress of the International Society for Organ Donation and Procurement. As Kevin explains in the presentation, the initiation of this clinical study is an important step toward our goal of dramatically expanding access to life-saving bone marrow transplants for blood cancer patients and enabling these procedures to be used far more broadly in the future. With our bone marrow available on-demand, patients can bypass the lengthy and uncertain process of identifying a living donor. Furthermore, patients will benefit from improved treatment outcomes due to the ability to obtain an optimized dose specific to their size and condition with lower T-cell counts.
“Our goal is to show that there’s no tradeoff between increasing the accessibility of a treatment, increasing the affordability of a treatment, and increasing the quality of a treatment. We really are shooting for all three,” summarized Kevin.
The presentation also includes an overview of Ossium’s studies of Graft-versus-Host Disease treatment and solid organ transplant tolerance induction.
Watch the full presentation below.